TY - JOUR
T1 - MiR-320a as a Potential Novel Circulating Biomarker of Arrhythmogenic CardioMyopathy
AU - Sommariva, Elena
AU - D'Alessandra, Yuri
AU - Farina, Floriana Maria
AU - Casella, Michela
AU - Cattaneo, Fabio
AU - Catto, Valentina
AU - Chiesa, Mattia
AU - Stadiotti, Ilaria
AU - Brambilla, Silvia
AU - Dello Russo, Antonio
AU - Carbucicchio, Corrado
AU - Vettor, Giulia
AU - Riggio, Daniela
AU - Sandri, Maria Teresa
AU - Barbuti, Andrea
AU - Vernillo, Gianluca
AU - Muratori, Manuela
AU - Dal Ferro, Matteo
AU - Sinagra, Gianfranco
AU - Moimas, Silvia
AU - Giacca, Mauro
AU - Colombo, Gualtiero Ivanoe
AU - Pompilio, Giulio
AU - Tondo, Claudio
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Diagnosis of Arrhythmogenic CardioMyopathy (ACM) is challenging and often late after disease onset. No circulating biomarkers are available to date. Given their involvement in several cardiovascular diseases, plasma microRNAs warranted investigation as potential non-invasive diagnostic tools in ACM. We sought to identify circulating microRNAs differentially expressed in ACM with respect to Healthy Controls (HC) and Idiopathic Ventricular Tachycardia patients (IVT), often in differential diagnosis. ACM and HC subjects were screened for plasmatic expression of 377 microRNAs and validation was performed in 36 ACM, 53 HC, 21 IVT. Variable importance in data partition was estimated through Random Forest analysis and accuracy by Receiver Operating Curves. Plasmatic miR-320a showed 0.53 ± 0.04 fold expression difference in ACM vs. HC (p < 0.01). A similar trend was observed when comparing ACM (n = 13) and HC (n = 17) with athletic lifestyle, a ACM precipitating factor. Importantly, ACM patients miR-320a showed 0.78 ± 0.05 fold expression change vs. IVT (p = 0.03). When compared to non-invasive ACM diagnostic parameters, miR-320a ranked highly in discriminating ACM vs. IVT and it increased their accuracy. Finally, miR-320a expression did not correlate with ACM severity. Our data suggest that miR-320a may be considered a novel potential biomarker of ACM, specifically useful in ACM vs. IVT differentiation.
AB - Diagnosis of Arrhythmogenic CardioMyopathy (ACM) is challenging and often late after disease onset. No circulating biomarkers are available to date. Given their involvement in several cardiovascular diseases, plasma microRNAs warranted investigation as potential non-invasive diagnostic tools in ACM. We sought to identify circulating microRNAs differentially expressed in ACM with respect to Healthy Controls (HC) and Idiopathic Ventricular Tachycardia patients (IVT), often in differential diagnosis. ACM and HC subjects were screened for plasmatic expression of 377 microRNAs and validation was performed in 36 ACM, 53 HC, 21 IVT. Variable importance in data partition was estimated through Random Forest analysis and accuracy by Receiver Operating Curves. Plasmatic miR-320a showed 0.53 ± 0.04 fold expression difference in ACM vs. HC (p < 0.01). A similar trend was observed when comparing ACM (n = 13) and HC (n = 17) with athletic lifestyle, a ACM precipitating factor. Importantly, ACM patients miR-320a showed 0.78 ± 0.05 fold expression change vs. IVT (p = 0.03). When compared to non-invasive ACM diagnostic parameters, miR-320a ranked highly in discriminating ACM vs. IVT and it increased their accuracy. Finally, miR-320a expression did not correlate with ACM severity. Our data suggest that miR-320a may be considered a novel potential biomarker of ACM, specifically useful in ACM vs. IVT differentiation.
UR - http://www.scopus.com/inward/record.url?scp=85021957647&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021957647&partnerID=8YFLogxK
U2 - 10.1038/s41598-017-05001-z
DO - 10.1038/s41598-017-05001-z
M3 - Article
AN - SCOPUS:85021957647
VL - 7
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 4802
ER -